Adas Darinskas
| Adas Darinskas | |
|---|---|
 Darinskas Adas.jpg | |
| Born | June 3, 1978 Vilnius, Lithuania |
| 🏳️ Nationality | Lithuanian |
| 🎓 Alma mater | Vilnius University |
| 💼 Occupation | Scientist, businessman |
| Known for | Advanced cancer immunology |
Adas Darinskas (born 3th June 1978) is a renowned Lithuanian scientist and businessman, holding a Doctorate in Biomedical Sciences from Vilnius University. Dr. Darinskas has established several leading biotech companies focused on advanced immunological treatments for oncology and other debilitating illnesses.
Education[edit]
Dr. Adas Darinskas has studied at Vilnius University focusing his scientific interests in molecular biology and genetics. In 2008 graduating with a PhD degree in Biomedical Sciences. Dr. Darinskas’ doctoral thesis concentrated on the "Isolation, characterization, transplantation of mouse fetal cells, evaluation of anti-inflammatory effects in mice and application to in vitro toxicity studies".
Later on, in 2016, Dr. Darinskas has been granted an additional Master’s degree at the University of Granada, which has certified him as a Qualified Person in Advanced Therapy Medicinal Products (ATMPs).
While Dr. Darinskas’ practical knowledge was attained working with cell and tissue engineering at Lithuania’s prime scientific organisations, such as:
- the Institute of Cardiology,
- the Institute of Immunology of Vilnius University and
- the National Cancer Institute [1]
Research[edit]
Dr. Adas Darinskas’ scientific interests mostly lie in immunology [2], oncology [3], and regenerative medicine [4], with equal importance being put on maintaining the highest quality and safety standards, such as the Good Laboratory Practice (GLP) and the Good Manufacturing Practices (GMP).
Dr. Adas Darinskas is continuously developing innovative technologies in:
- stem cells;
- cell scaffold designs;
- subcellular components (exosomes, transport of mitochondria);
- CAR-T technology;
- nanotechnologies in medicine;
- further development of molecular biology techniques in manufacturing of Advanced Therapy Medicinal Products.
Dr. Darinskas holds 3 technological patents and has also co-patented 2 other technologies. These being:
- Obtaining method of dendritic cells (ld) from peripheral blood, bone marrow or apherasis product and use thereof (in 2016).
- Method of isolation stromal vascular fraction (svf) cells from adipose tissue and their use (in 2015).
- Method of production of cytokine induced/activated killer cells from peripherial blood, bone marrow or apheresis product and use thereof (2019).
- Xenogenic normal tissue-derived vaccines for breaking the immune tolerance to tumor-associated antigens (in 2014).
- Method of eye drop preparation and use thereof (in 2016).
Career[edit]
While Dr. Darinskas has been an active participant of scientific community, he has also ventured into biotech business, starting in 2005, when he established Innovita Research - an organisation which has been working on various significant scientific research projects [5] related to immunology and regenerative medicine, which includes mesenchymal stem cells, xenogeneic vaccines, and forward-thinking antiaging technologies.
In 2006, Dr. Adas Darinskas has co-founded a private stem cell bank in Lithuania [6], which was the first licenced stem cell bank in the Baltic States. Later, the bank was sold to foreign investors and in 2018 became part of the largest stem cell bank networks in Europe - VITA34.
In 2013 Dr. Adas Darinskas has also co-founded another biotechnology start-up – Froceth, which was and remains a prime manufacturer of Advanced Therapy Medicinal Products (ATMPs) in the Baltic States and the Region.
This company works on the manufacturing of Advanced Therapy Medicinal Products for cancer immunotherapy, multiple sclerosis, tissue regeneration and other illnesses. While at the same time, Froceth carries a licence for production of Investigational ATMPs and collaborates with other European institutions in organising particular scientific trails in this field. Needless to mention, that the company carries out its processes solely according to the Good Manufacturing Practice (GMP).
In order to work with patients directly in offering innovative and advanced treatment solutions, in 2019, Innovita Research has branched out to open a specialised clinic in Vilnius, Lithuania, which gives its patients access to new, state-of-the-art therapies.
Social responsibility[edit]
Although, advances in scientific research have been an integral part of Dr. Adas Darisnkas’ activities, in his view, it is equally important to give back to society. Thus, Dr. Darinskas has established a first public cord blood and tissue bank in Lithuania, which allows all pregnant women to participate free of charge in creating a universal bank which will be accessible to all the people of the Republic of Lithuania.
Publications[edit]
- Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography. Mačiulaitis J, Deveikytė M, Rekštytė S, Bratchikov M, Darinskas A, Šimbelytė A, Daunoras G, Laurinavičienė A, Laurinavičius A, Gudas R, Malinauskas M, Mačiulaitis R.Biofabrication. 2015 Mar 23;7(1):015015. doi: 10.1088/1758-5090/7/1/015015.PMID: 25797444
- Protein oligomerization induced by oleic acid at the solid-liquid interface--equine lysozyme cytotoxic complexes. Wilhelm K, Darinskas A, Noppe W, Duchardt E, Mok KH, Vukojević V, Schleucher J, Morozova-Roche LA.FEBS J. 2009 Aug;276(15):3975-89. doi: 10.1111/j.1742-4658.2009.07107.x. Epub 2009 Jul 7.PMID: 19594832
- Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. Wilhelm KR, Yanamandra K, Gruden MA, Zamotin V, Malisauskas M, Casaite V, Darinskas A, Forsgren L, Morozova-Roche LA.Eur J Neurol. 2007 Mar;14(3):327-34. doi: 10.1111/j.1468-1331.2006.01667.x.PMID: 17355556
- Does the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicity? Malisauskas M, Ostman J, Darinskas A, Zamotin V, Liutkevicius E, Lundgren E, Morozova-Roche LA.J Biol Chem. 2005 Feb 25;280(8):6269-75. doi: 10.1074/jbc.M407273200. Epub 2004 Dec 1.PMID: 15576361
- Osteochondral Repair and Electromechanical Evaluation of Custom 3D Scaffold Microstructured by Direct Laser Writing Lithography. Maciulaitis J, Miskiniene M, Rekštytė S, Bratchikov M, Darinskas A, Simbelyte A, Daunoras G, Laurinaviciene A, Laurinavicius A, Gudas R, Malinauskas M, Maciulaitis R.Cartilage. 2019 May 9:1947603519847745. doi: 10.1177/1947603519847745. Online ahead of print.PMID: 31072136
- Engrafting fetal liver cells into multiple tissues of healthy adult mice without the use of immunosuppressants. Darinskas A, Gasparaviciute R, Malisauskas M, Wilhelm K, Kozhevnikov JA, Liutkevicius E, Pilinkiene A, Morozova-Roche LA.Cell Mol Biol Lett. 2007 Sep;12(3):422-34. doi: 10.2478/s11658-007-0013-2. Epub 2007 May 10.PMID: 17361367
- Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J.Stem Cells Dev. 2012 Sep 20;21(14):2724-52. doi: 10.1089/scd.2011.0722. Epub 2012 May 9.PMID: 22468918 Review.
- Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines. Dobrovolskienė N, Pašukonienė V, Darinskas A, Kraśko JA, Žilionytė K, Mlynska A, Gudlevičienė Ž, Mišeikytė-Kaubrienė E, Schijns V, Lubitz W, Kudela P, Strioga M.Vaccine. 2018 Jul 5;36(29):4171-4180. doi: 10.1016/j.vaccine.2018.06.016. Epub 2018 Jun 9.PMID: 29895501
- Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Ostapenko V, Schijns V.Vaccine. 2014 Jul 7;32(32):4015-24. doi: 10.1016/j.vaccine.2014.05.006. Epub 2014 May 14.PMID: 24837511 Review.
- Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. Kraśko JA, Žilionytė K, Darinskas A, Strioga M, Rjabceva S, Zalutsky I, Derevyanko M, Kulchitsky V, Lubitz W, Kudela P, Miseikyte-Kaubriene E, Karaman O, Didenko H, Potebnya H, Chekhun V, Pašukonienė V.Oncol Rep. 2017 Jan;37(1):171-178. doi: 10.3892/or.2016.5252. Epub 2016 Nov 16.PMID: 27878261
- Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy. Kazlauskas A, Darinskas A, Meškys R, Tamašauskas A, Urbonavičius J.BMC Cancer. 2019 Mar 4;19(1):197. doi: 10.1186/s12885-019-5409-7.PMID: 30832616
- Bone regeneration in rabbit calvarial defects using PRGF and adipose-derived stem cells: histomorphometrical analysis. Stumbras A, Kuliesius P, Darinskas A, Kubilius R, Zigmantaite V, Juodzbalys G.Regen Med. 2020 Apr;15(4):1535-1549. doi: 10.2217/rme-2019-0123. Epub 2020 May 26.PMID: 32452715
- Intermediate amyloid oligomers of lysozyme: Is their cytotoxicity a particular case or general rule for amyloid? Malisauskas M, Darinskas A, Zamotin VV, Gharibyan A, Kostanyan IA, Morozova-Roche LA.Biochemistry (Mosc). 2006 May;71(5):505-12. doi: 10.1134/s0006297906050063.PMID: 16732728
- Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model. Kraśko JA, Žilionytė K, Darinskas A, Dobrovolskienė N, Mlynska A, Riabceva S, Zalutsky I, Derevyanko M, Kulchitsky V, Karaman O, Fedosova N, Symchych TV, Didenko G, Chekhun V, Strioga M, Pašukonienė V.Oncol Lett. 2018 Apr;15(4):5098-5104. doi: 10.3892/ol.2018.7950. Epub 2018 Feb 5.PMID: 29552144
- Scaffold design for artificial tissue with bone marrow stem cells. Noreikaitė A, Antanavičiūtė I, Mikalayeva V, Darinskas A, Tamulevičius T, Adomavičiūtė E, Šimatonis L, Akramienė D, Stankevičius E.Medicina (Kaunas). 2017;53(3):203-210. doi: 10.1016/j.medici.2017.07.001. Epub 2017 Jul 13.PMID: 28774494
- Stromal vascular fraction cell therapy for osteoarthritis in elderly: Multicenter case-control study. Michalek J, Vrablikova A, Darinskas A, Lukac L, Prucha J, Skopalik J, Travnik J, Cibulka M, Dudasova Z.J Clin Orthop Trauma. 2019 Jan-Feb;10(1):76-80. doi: 10.1016/j.jcot.2018.11.010. Epub 2018 Nov 23.PMID: 30705536 No abstract available.
References[edit]
- ↑ “Onkologinių ligonių imuninės sistemos stiprinimas” Lietuvos gydytojo žurnalas. 2019 Nr. 2 Retrieved [2020-12-11].
- ↑ Ugnė Vedeikaitė.“Vėžio ląstelės tūno visų žmonių kūnuose: mokslininkas įvardijo dažniausią priežastį, kodėl liga prabunda” DELFI. Retrieved [2020-12-11]
- ↑ 15min. “Lietuva kuria unikalius vaistus nuo vėžio”. Retrieved [2020-12-11]
- ↑ lrytas.lt. “Likimo smūgis jaunam vilniečiui: negailestinga diagonozė tebuvo pradžia” Retrieved [2020-12-11]
- ↑ Lithuanian university of health sciences. Research information system. Retrieved [2020-12-11]
- ↑ “Kamieninių ląstelių bankas atveria laboraotriją” Retrieved [2020-12-11]
This article "Adas Darinskas" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Adas Darinskas. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
